Skip to content

Updates: Company News - Page 2

An experiment being carried out
13th April, 2021

NB collaborates with Takeda Pharmaceuticals on renal drug safety evaluation study

Newcells Biotech and Takeda Pharmaceutical International Co. have collaborated in a study designed to assess drug safety. The study evaluated a set of 36 known drugs and…

Read update
Newcells Secure Investment
23rd February, 2021

Newcells Biotech secures over £5m for 3D tissue models

Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25m worth of funding to accelerate their growth plans in the international life sciences market.The funding…

Read update
Newcells scales up its operations in the biosphere
26th June, 2020

Newcells scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory 

Read update
Newcells Biotech Covid-19 Action Plan
18th March, 2020

Covid-19 action plan – A message to our customers, collaboration partners & colleagues

As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in…

Read update
Hepatic structure
16th December, 2019

NB win Phase II of CRACK IT Challenge 29: ImmuLiver

Newcells Biotech are excited to announce that they are Phase II contract winners of the NC3Rs-funded CRACK IT Challenge (named ImmuLiver). They have been awarded a further funding to…

Read update
Current Protocols in Stem Cell Biology
22nd October, 2019

Newcells Biotech acquires IP for retinal organoids

Newcells Biotech  is pleased to announce the acquisition of intellectual property pertaining to the methodology for the differentiation of three-dimensional retinal org

Read update
Newcells Biotech
18th July, 2019

Dr Frank Armstrong appointed as Non-executive Director

Newcells Biotech is pleased to announce that it has appointed Dr Frank Armstrong to its Board as a Non-executive Director. “Attracting an executive of Frank’s proven track-record and…

Read update
Hepatic structure
24th April, 2019

NB win Phase I of CRACK IT Challenge 29: ImmuLiver – securing £99,711 funding

Newcells Biotech are one…

Read update
2018 Year in Review Image
20th December, 2018

Looking forward: A year in review

2018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team.   Here are some of…

Read update
ESTIV 2018 Internation Congress
9th November, 2018

ESTIV 2018 International Congress

Congress Round-Up The International Congress on In Vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018.  This year marks its 20th meeting, with the general theme of new…

Read update
Dr Colin Brown appointment image
13th September, 2018

Leading drug transport & drug toxicity expert, Dr Colin Brown joins NB

Newcells Biotech has announced that Dr Colin Brown, one of the world’s leading experts on drug transport and drug toxicity in kidney will join the company as Director of ADMET Technology….

Read update
22nd North American ISSX Meeting - Montreal, Canada
11th July, 2018

22nd North American ISSX Meeting – Montréal, Canada (15th-19th July)

The meeting brings together individuals who are working on drug/xenobiotic research across a diverse range of fields such as clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal…

Read update

Get our latest updates straight to your inbox